Heavy menstrual bleeding, or having heavy periods, is a major problem for many women. Women with heavy periods may suffer lessened quality of life, may have to spend time out of work, and may have to cancel plans with family and friends because of their symptoms. Health care providers want to help women get the best treatments for their heavy periods. We want to help women get the best treatments for their heavy bleeding.
In the United States, the two most common non-surgical treatment options are the levonogestrel intrauterine system (LNG-IUS) and combined oral contraceptives. Researchers seek to determine which of these two treatment options is more effective in improving quality of life for women with heavy or irregular menstrual bleeding.
If you are interested in hearing more about the study, please contact our study staff at (401) 274-1122, ext. 48549 or email at researchSHiPP@carene.org
All participants will:
Be randomly assigned to one of the two non-surgical treatment groups - the levonogestrel intrauterine system (LNG-IUS) or combined oral contraceptives.
Be asked to complete a questionnaire and a diary that includes your period cycle, medical history, and background information.
Continue with recommended clinical care with your own ob/gyn provider.
Be asked to complete up to six questionnaires over a one year period.
What you need to know:
Study participation is voluntary
Participants will be compensated
Patients receive $100 at each monthly study infusion and at the one and two year infant follow- ups.
CMV is common virus spread like a cold or flu. If a woman is infected for the first time while pregnant, there is a 40 percent chance the fetus will also be infected. These fetuses are more likely to be born earlier, have low birth weight, or smaller heads. Some of these babies will develop problems such as hearing loss and learning disabilities. There is currently no approved treatment for CMV.